QuidelOrtho Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a QDEL research report →
Range $12 – $12.5
Price Chart
About the company
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression.
- CEO
- Brian J. Blaser
- IPO
- 1991
- Employees
- 6,500
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on QDEL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $570.86M
- P/E
- -1.76
- Fwd P/E
- 12.51
- PEG
- -0.02
- P/S
- 0.25
- P/B
- 0.37
- EV/EBITDA
- 11.03
- Div Yield
- 0.00%
- Gross Margin
- 44.22%
- Op Margin
- -4.74%
- Net Margin
- -14.24%
- ROE
- -20.13%
- ROIC
- -2.38%
Latest fiscal year · YoY change
- Revenue
- $2.73B-1.9%
- Gross Profit
- $1.27B-1.0%
- Op Income
- $-919,200,000
- Net Income
- $-1,131,800,000+44.8%
- EPS
- $-16.69+45.4%
- OCF Growth
- +26.7%
- FCF Growth
- +26.0%
- 52W High
- $35.58
- 52W Low
- $8.06
- 50D MA
- $12.04
- 200D MA
- $15.01
- Beta
- 0.68
- RSI (14)
- 29
- Avg Volume
- 2.03M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
QuidelOrtho’s quarter was pressured by China pricing changes and softer respiratory testing, but core labs and immunohematology still grew and management launched a major restructuring to improve margins and cash flow.· November 3, 2026
- Total revenue was $619 million, down 12% year over year; excluding China, respiratory and the donor screening wind-down, revenue rose 3%.
- Labs outside China grew 4% and immunohematology outside China grew 3%, showing resilience in the core franchise.
- Point of Care fell 27%, including a 39% drop in respiratory revenue, and management kept a cautious near-term view on respiratory.
- China revenue declined 45% as distributors and customers destocked ahead of nationwide IVD pricing changes; management expects continued destocking in 2026 and more pricing pressure in 2027.
- The company announced a new restructuring program expected to deliver more than $80 million of annual savings in 2027, with $30 million to $35 million of one-time charges in Q4.
Third-quarter reported revenue was $619 million, down 12% year over year. Excluding China, respiratory and the prior-year donor screening business, revenue increased 3%. Labs outside China grew 4% and immunohematology outside China grew 3%, while Point of Care declined 27% and respiratory declined 39%. China revenue fell 45% year over year. Adjusted gross margin was 47.8%, down 90 basis points year over year. Adjusted EBITDA was $148 million, a 24% margin, and adjusted EPS was $0.31. Operating cash flow was $20 million, net capital expenditures were $19 million, and free cash flow was approximately breakeven versus negative $95 million last year. For full-year 2026, revenue guidance was narrowed to $2.52 billion to $2.54 billion from $2.52 billion to $2.6 billion, adjusted EBITDA is expected to be $540 million to $545 million, and adjusted EPS is expected to be $0.65 to $0.70.
Brian Blaser said the business remains resilient underneath the headline pressure, with labs and immunohematology representing 70% to 75% of revenue excluding China and growing at low to mid-single-digit rates. He framed the new operating model as a shift from a regional structure to two focused businesses, core diagnostics and Point of Care, meant to improve customer focus, accountability, profitability and cash generation. His tone was pragmatic and decisive, emphasizing that the restructuring is not just about cutting cost but about strengthening the business long term.
Micah Young focused on execution against his priorities of better operating discipline, stronger cash conversion and lower leverage. He said the restructuring should generate more than $80 million of annual savings in 2027, with approximately $30 million to $35 million of one-time restructuring charges in Q4 and most of the cash outflow also in Q4. He highlighted improvement in cash flow, with operating cash flow of $20 million and free cash flow near breakeven, while noting net debt of approximately $2.8 billion, net leverage of 4.5x adjusted EBITDA, and cash of $166 million. He also said the company amended its credit agreement to raise the maximum consolidated leverage ratio to 5.5x through Q2 2028.
Analysts pressed management on the new business-unit structure, asking what practically changes versus the prior regional model; management said the new setup should create clearer accountability, more customer focus, and better alignment of development and investment priorities. Questions also focused on free cash flow and what is holding it back; Micah pointed to cost structure, working capital efficiency and capital expenditures, and said the company is seeing some progress but still has work to do. Analysts asked about China’s outlook and whether an asset sale was possible; Brian said the company still believes its economics in China remain favorable and that it will consider all alternatives to optimize shareholder value, but he would not comment on rumors.
The positive case from the call is that QuidelOrtho’s core labs and immunohematology franchises are still growing despite the China and respiratory drag, and management says those businesses have durable customer relationships and a large installed base. The restructuring could materially improve the earnings profile, with over $80 million of annual savings expected in 2027 and explicit focus on cash flow and deleveraging.
The main risks are that China remains a significant headwind, with management expecting continued destocking through the rest of 2026 and more pricing pressure in 2027 as provincial implementation rolls through. Respiratory demand also remains uncertain, and management kept a cautious outlook for the balance of the year. On top of that, the restructuring brings one-time charges in Q4 and the company is still carrying elevated leverage at 4.5x adjusted EBITDA.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.1%
- Shares Outstanding
- 68.61M
- Float Shares
- 68.00M
of shares held by institutions
256 13F filers
Buy/sell ratio 0.67. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for QDEL, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Daniel GoldmanHouse · NY10 | Sell | Jul 12, 23 | Filing → |
| Tom MalinowskiHouse · NJ07 | Buy | May 11, 21 | Filing → |
| Tom MalinowskiHouse · NJ07 | Sell | Apr 27, 21 | Filing → |
| Tom MalinowskiHouse · NJ07 | Sell | Mar 14, 21 | Filing → |
| Tom MalinowskiHouse · NJ07 | Sell | Mar 3, 21 | Filing → |
| Tom MalinowskiHouse · NJ07 | Sell | Feb 23, 21 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Nov 13, 20 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Nov 11, 20 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Jul 30, 20 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Jul 13, 20 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Jul 8, 20 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | May 21, 20 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Mar 10, 20 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Mar 2, 20 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 11.14M | ▼ 59.52K |
| Vanguard Group Inc | 7.57M | ▼ 64.12K |
| Newtyn Management, LLC | 6.63M | ▲ 2.07M |
| Fmr LLC | 3.95M | ▼ 3.41M |
| American Century Companies Inc | 3.93M | ▲ 619.55K |
| Vanguard Portfolio Management LLC | 3.64M | ▼ 499.69K |
| Invesco Ltd. | 3.60M | ▲ 131.38K |
| Rubric Capital Management LP | 3.31M | 0 |
| State Street Corp | 3.03M | ▲ 47.99K |
| Vanguard Capital Management LLC | 3.02M | ▼ 54.47K |
| Neuberger Berman Group LLC | 2.95M | ▼ 584.75K |
| Paradigm Capital Management Inc/Ny | 2.39M | ▼ 131.40K |
Held by 323 ETFs
Biggest fund positions in QDEL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 15, 26 | Siegrist Jonathan Philip | other | 18,657 |
| Oct 15, 26 | Siegrist Jonathan Philip | other | 6,695 |
| Oct 15, 26 | Siegrist Jonathan Philip | other | 18,657 |
| Sep 15, 26 | Bowman Ronald Lee | other | 2,566 |
| Sep 15, 26 | Bowman Ronald Lee | other | 921 |
| Sep 15, 26 | Bowman Ronald Lee | other | 2,566 |
| Aug 15, 26 | Hanson Bryan Michael | other | 446 |
| Aug 15, 26 | Hanson Bryan Michael | other | 162 |
| Aug 15, 26 | Hanson Bryan Michael | other | 446 |
| Jul 15, 26 | Young Micah W | other | 356,555 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our QDEL coverage
Recent articles, reports, and earnings notes.

What to Watch as DRC Medicine's SPAC Merger Heads to Close
DRC Medicine is a Tokyo-based healthcare and biotech company going public via a merger with Ribbon Acquisition Corp. (NASDAQ: RIBB). The setup offers a development-stage story with real upside if its mask, diagnostics, and certification pipeline advances, but shareholders should watch redemption risk and dilution closely.

What to Watch as Cue Health Prices Its Nasdaq IPO
Cue Health Inc. (NASDAQ: HLTH) is expected to list on 2026-07-21 in a priced deal with a $15 to $17 range. The company is pitching connected diagnostics and at-home testing, but shareholders should watch how much of the story still depends on testing demand and regulatory execution.
Want a deeper read on QDEL?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
QuidelOrtho Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of QuidelOrtho Corporation - QDEL
prnewswire.com · Nov 20
QuidelOrtho (QDEL) Securities Investigation Notice - Levi & Korsinsky
gurufocus.com · Nov 16
QuidelOrtho (QDEL) Securities Investigation Notice - Levi & Korsinsky
prnewswire.com · Nov 16
Did QuidelOrtho Corporation Insiders Breach their Fiduciary Duties to Shareholders?
prnewswire.com · Nov 12
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving QuidelOrtho (QDEL)
globenewswire.com · Nov 12
QuidelOrtho Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of QuidelOrtho Corporation - QDEL
businesswire.com · Nov 11
QDEL SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving QuidelOrtho
prnewswire.com · Nov 10
QuidelOrtho Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into QuidelOrtho (QDEL)
prnewswire.com · Nov 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.